Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T O'Neill

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Drug Information Journal|December 11, 1986
Statistical analyses of adverse event data from clinical trials. Special emphasis on serious eventsR T O'Neill
Statistics in Medicine|September 28, 1998
Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studiesR T O'Neill
American Journal of Obstetrics and Gynecology|September 15, 1970
Pregnancy following hormonal therapy for adenocarcinoma of the endometriumR T O'Neill
Statistics in Medicine|March 1, 1993
Some FDA perspectives on data monitoring in clinical trials in drug developmentR T O'Neill
Statistics in Medicine|March 29, 2000
Commentary on 'Alpha calculus in clinical trials: considerations and commentary for the new millennium'R T O'Neill
Statistics in Medicine|December 1, 1988
On sample sizes to estimate the protective efficacy of a vaccineR T O'Neill
Controlled Clinical Trials|December 31, 1997
Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significanceR T O'Neill
American Journal of Epidemiology|July 1, 1984
Sample sizes for estimation of the odds ratio in unmatched case-control studiesR T O'Neill
Statistics in Medicine|May 15, 1995
Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonizationR T O'Neill
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
FDA's critical path initiative: a perspective on contributions of biostatisticsR T O'Neill
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Drug Information Journal|December 11, 1986
Statistical analyses of adverse event data from clinical trials. Special emphasis on serious eventsR T O'Neill
Statistics in Medicine|September 28, 1998
Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studiesR T O'Neill
American Journal of Obstetrics and Gynecology|September 15, 1970
Pregnancy following hormonal therapy for adenocarcinoma of the endometriumR T O'Neill
Statistics in Medicine|March 1, 1993
Some FDA perspectives on data monitoring in clinical trials in drug developmentR T O'Neill
Statistics in Medicine|March 29, 2000
Commentary on 'Alpha calculus in clinical trials: considerations and commentary for the new millennium'R T O'Neill
Statistics in Medicine|December 1, 1988
On sample sizes to estimate the protective efficacy of a vaccineR T O'Neill
Controlled Clinical Trials|December 31, 1997
Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significanceR T O'Neill
American Journal of Epidemiology|July 1, 1984
Sample sizes for estimation of the odds ratio in unmatched case-control studiesR T O'Neill
Statistics in Medicine|May 15, 1995
Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonizationR T O'Neill
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
FDA's critical path initiative: a perspective on contributions of biostatisticsR T O'Neill
Pageof 4